These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7534978)

  • 21. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
    Wilhelm M; O'Brien S; Rios MB; Estey E; Keating MJ; Plunkett W; Sorenson M; Kantarjian HM
    Leuk Lymphoma; 1999 Aug; 34(5-6):511-8. PubMed ID: 10492074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
    Amato R; Ho D; Schmidt S; Krakoff IH; Raber M
    Cancer Chemother Pharmacol; 1992; 30(4):321-4. PubMed ID: 1379523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM; Piver MS; Hempling RE; Recio FO
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study.
    Hurteau JA; Blessing JA; DeCesare SL; Creasman WT
    Gynecol Oncol; 2001 Jul; 82(1):7-10. PubMed ID: 11426954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group.
    Manetta A; Blessing JA; Hurteau JA
    Gynecol Oncol; 1998 Jan; 68(1):45-6. PubMed ID: 9454659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Hoffman MA; Blessing JA; Nuñez ER
    Gynecol Oncol; 2001 Jun; 81(3):433-5. PubMed ID: 11371134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Kavanagh JJ; Sill MW; Ramirez PT; Warshal D; Pearl ML; Morgan MA
    Int J Gynecol Cancer; 2008; 18(3):460-4. PubMed ID: 17854432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
    Shoji T; Takatori E; Omi H; Kumagai S; Yoshizaki A; Yokoyama Y; Mizunuma H; Fujimoto T; Takano T; Yaegashi N; Tase T; Nakahara K; Kurachi H; Nishiyama H; Sugiyama T
    Int J Gynecol Cancer; 2011 Jan; 21(1):44-50. PubMed ID: 21330830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Blessing JA; Baker VV; Barnhill DR; Adelson MD
    Am J Clin Oncol; 1990 Aug; 13(4):299-301. PubMed ID: 2198794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W;
    Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
    Hochster H; Chen TT; Lu JM; Hills D; Sorich J; Escalon J; Ivy P; Liebes L; Muggia F
    Gynecol Oncol; 2008 Mar; 108(3):500-4. PubMed ID: 18191187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS; Blessing JA; Lentz SS; McMeekin DS
    Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
    Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
    Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
    Hoffman MA; Blessing JA; Morgan M
    Gynecol Oncol; 2000 Dec; 79(3):463-5. PubMed ID: 11104620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M; Rose PG
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Hoffman MA; Blessing JA; Lentz SS;
    Gynecol Oncol; 2003 Apr; 89(1):95-8. PubMed ID: 12694660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of fazarabine in advanced colorectal carcinoma.
    Hubbard KP; Daugherty K; Ajani JA; Pazdur R; Levin B; Abbruzzese JL
    Invest New Drugs; 1992 Apr; 10(1):39-42. PubMed ID: 1376722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.